W1M Asset Management Ltd Makes New $408.01 Million Investment in Thermo Fisher Scientific Inc. $TMO

W1M Asset Management Ltd bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 814,886 shares of the medical research company’s stock, valued at approximately $408,009,000. Thermo Fisher Scientific accounts for approximately 3.7% of W1M Asset Management Ltd’s holdings, making the stock its 11th biggest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Darwin Wealth Management LLC purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $170,000. Raymond James Financial Inc. boosted its holdings in shares of Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after purchasing an additional 53,542 shares during the period. Finally, California State Teachers Retirement System grew its position in Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,493 shares of company stock worth $37,657,681 in the last quarter. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Up 0.2%

Shares of NYSE:TMO opened at $629.02 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $232.58 billion, a PE ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm has a fifty day moving average price of $542.53 and a 200 day moving average price of $509.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Analyst Ratings Changes

A number of research firms have issued reports on TMO. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Royal Bank Of Canada upped their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.